Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

The Lancet

Volumn 346, Issue 8990, 1995, Pages 1593-1596

  Bloemenkamp, K W M ^a   Helmerhorst, F M ^a   Rosendaal, F R ^a   Vandenbroucke, J P ^a   Buller H R ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; CONTRACEPTIVE AGENT; DESOGESTREL; GESTAGEN; LEVONORGESTREL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CASE CONTROL STUDY; CONTRACEPTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREMENOPAUSE; PRIORITY JOURNAL;

EID: 0029609256     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)91929-5     Document Type: Article

References (15)

1. contraceptives a report to the Committee on Safety of Drugs
2. Oral contraceptives and venous thromboembolism: findings in a large prospective study
3. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
4. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content
5. Low-dose combined oral contraceptives
6. Evaluation of a new generation of oral contraceptives
7. New progestogens in oral contraception
8. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation
9. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
10. Mutation in blood coagulation factor V associated with resistance to activated protein C
11. The natural history and epidemiology of venous thrombosis
12. The risk of deep venous thrombosis: a computerized epidemiologic approach
13. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study
14. Oral contraceptive use in relation to myocardial infarction